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Introduction
The  Sixth  Joint  Cold  Spring  Harbor/Wellcome  Trust 
Centre Conference reported on new improvements that 
could affect ‘personalized medicine’ for the treatment of 
various  diseases.  Even  though  the  term  ‘pharmaco­
genetics’  was  coined  over  40  years  ago,  personalized 
medicine has become increasingly recognized in the past 
few years. The basic concept is to prescribe drugs accord­
ing to genetic profiles or other tests that give evidence for 
tailoring  treatments  to  patients,  potentially  improving 
care and saving money. It has been recognized for a long 
time that there is considerable inter­individual variation 
in the level of therapeutic responses to most drugs [1,2], 
and the same applies to the occurrence of adverse drug 
reactions. Some experts believe that most drugs currently 
on the market work for only a portion of the patients who 
take them, while countless patients are exposed to useless 
and/or toxic medications. This situation is a drawback of 
the ‘one size fits all’ approach of conventional phase 3 
studies in which the treatment that seems to be superior 
on  average  will  then  be  recommended  for  all  patients 
with  the  same  disease.  This  is  a  global  rather  than 
individual evaluation that determines the best treatment 
for  a  group  of  patients  without  distinguishing  the 
fortunate few who will really benefit from it.
Genome-wide association studies: a new paradigm 
for pharmacogenomics?
Although  individualization  of  certain  treatments  had 
been carried out in the pre­genomic era, recent progress 
in personalized medicine follows advances in molecular 
diagnostics  and  genomic  technologies.  In  the  past  4 
years,  genome­wide  association  studies  (GWASs)  have 
emerged  as  a  powerful  tool  to  identify  disease­related 
genes  for  many  common  human  disorders  [3].  This 
hypothesis­free approach now provides useful informa­
tion in the context of drug safety and efficacy. Data from 
the  National  Human  Genome  Research  Institute 
(NHGRI) GWAS catalog [http://genome.gov/gwastudies] 
show that the number of published GWASs exceeded 400 
in September 2009. Careful analysis of this catalog also 
reveals that the number of pharmacogenomics GWASs is 
beginning  to  accumulate,  with  24  studies  that  have 
specifically  examined  a  drug­induced  phenotype  and 
genome­wide  single  nucleotide  polymorphism  markers 
(Figure 1). Even if these represent less than 10% of the 
overall number of studies, 15 pharmacogenomics GWASs 
were published during 2009. Most of these studies have 
succeeded in identifying associations between common 
genetic variants and common drug­related phenotypes, 
including  changes  in  drug  efficacy  or  occurrence  of 
adverse drug reactions.
Recent advances from pharmacogenomics GWASs
Many new GWASs were discussed during the meeting, 
many focusing on the genetic determinants of response 
to antithrombotic agents. Stephane Bourgeois (Wellcome 
Trust Sanger Institute, Hinxton, UK) presented a GWAS 
that  identified  novel  loci  that  may  be  implicated  in 
patients’ responses to the antithrombotic agent warfarin. 
These  data  may  allow  the  further  development  of 
algorithms that help predict warfarin dose.
I showed data on the genetic determinants of clopido­
grel response. Clopidogrel is key for prevention of arterial 
thrombotic  complications,  and  it  can  be  used  in  the 
treatment of acute coronary syndromes, ischemic cere­
bral infarction and established peripheral arterial disease. 
A recent GWAS was conducted by Shuldiner et al. [4], 
who  administered  clopidogrel  to  a  population  of  429 
healthy Amish people and then genotyped the partici­
pants to identify the loss­of­function variant CYP2C19*2, 
which  they  found  to  be  associated  with  a  diminished 
biological response to the drug. They then replicated the 
findings  in  an  independent  sample  of  227  patients 
Abstract
A report on the Joint Cold Spring Harbor/Wellcome 
Trust Conference ‘Pharmacogenomics and Personalized 
Medicine’, Hinxton, UK, 12-15 September 2009.
© 2010 BioMed Central Ltd





Cardiovascular Research Center, Mount Sinai School of Medicine, One Gustave 
L Levy Place, Box 1030, New York, NY 10029, USA 
Pharmacology department, UPMC Paris 6, Assistance Publique Hôpitaux de Paris, 
Hôpital Pitié-Salpêtrière, 47 Boulevard de l’hôpital, 75013 Paris, France
Hulot Genome Medicine 2010, 2:13 
http://genomemedicine.com/content/2/2/13
© 2010 BioMed Central Ltdundergoing  percutaneous  coronary  intervention  and 
found  that  among  those  taking  clopidogrel,  carriers  of 
the CYP2C19*2 variant had a 2.42 higher risk of having a 
cardiovascular  ischemic  event  or  of  dying  during  the 
following year. The findings from this first GWAS are in 
agreement  with  previous  results  from  candidate  gene 
studies in this field [5­7], as presented during the meeting.
Another example concerns the occurrence of myopathy 
in patients treated with statins, as presented by Emma 
Link  (Clinical  Trial  Service  Unit  and  Epidemiological 
Studies Unit, University of Oxford, UK), Ronald Krauss 
(Children’s  Hospital  Oakland  Research  Institute, 
Oakland,  USA)  and  Bas  Peters  (University  of  Utrecht, 
The  Netherlands).  The  SEARCH  (Study  of  the 
Effectiveness  of  Additional  Reductions  in  Cholesterol 
and  Homocysteine)  collaborative  group  identified  85 
patients suffering from statin­induced myopathy among 
12,064 post­myocardial infarction patients included in a 
randomized clinical trial that compared a high dose (80 
mg)  with  a  low  dose  (20  mg)  of  simvastatin  [8].  By 
performing a genome­wide analysis in 85 patients and 90 
controls,  they  identified  a  strong  association  with  a 
genetic variant within the SLCO1B1 gene, which encodes 
a transporter involved in the hepatic uptake of statins. 
More than 60% of the myopathy cases could be attributed 
to the mutated variant [8].
Pharmacogenomics information is available for 
almost all of the best-selling drugs
Many other examples were reported during the meeting. 
Concerning anti­mitotic drugs, Hiltrud Brauch (Institute 
of  Clinical  Pharmacology,  Stuttgart,  Germany)  and 
William  Newman  (University  of  Manchester,  UK) 
reported  on  the  modulation  of  tamoxifen  efficacy  in 
breast  cancer  patients  according  to  cytochrome  p450 
2D6 genetic variants. Other studies on psychotropes and 
anti­depressant  or  anti­infectious  therapies  (such  as 
hypersensitivity reactions to the anti­HIV agent abacavir) 
were  presented.  These  examples  highlight  the  recent 
genetic  discoveries  that  have  raised  the  prospect  of 
testing  patients  for  these  variants  before  they  are 
prescribed drugs, so that those at risk of lack of response 
or of adverse drug reactions can be considered for other 
treatment  options  or  careful  monitoring.  This  new 
information  concerns  many  of  the  most  widely  used 
drugs in the world: so far, pharmacogenomics informa­
tion (and thus the perspective for personalized prescrip­
tion) exists for almost all of the top ten best­selling drugs 
of the world (Table 1).
As  pointed  out  by  Urs  Meyer  (University  of  Basel, 
Switzerland), we can estimate that more than 40 pharma­
co  genetic conditions ­ that is, conditions in which varia­
tions  in  the  sequence  of  a  particular  gene  has  been 
associated with alteration in drug response or toxicity ­ 
have been described in more than one clinical study [9]. 
This observation is important given that 2.5 to 12% of 
hospital  admissions  and  0.4  to  0.5%  of  deaths  are 
probably related to adverse drug reactions [10]. As shown 
by  Shashi  Amur  (US  Food  and  Drug  Administration 
(FDA), Washington DC, USA) the FDA recently modified 
numerous drug labels to recommend or require genetic 
testing before drug prescription. At the same time, the 
FDA cleared for marketing molecular assays to promote 
personalized drug treatment decisions. For instance, the 
FDA  has  urged  for  testing  for  HLA-B*5701  before  the 
prescription of the anti­HIV drug abacavir. It is estimated 
that two thirds of HLA-B*5701 allele carriers (around 6% 
of patients) will develop life­threatening hypersensitivity 
reactions. Moreover, HLA-B*5701 prescreening reduced 
the incidence of hypersensitivity reactions to abacavir by 
50% compared to a strategy without prescreening [11]. 
Other examples were also reported ­ notably, for cancer 
patients  [12],  TPMT  and  aziathropine,  UGT1A1  and 
irinotecan,  and  others  ­  showing  the  potential  for 
personalized medicine development.
Future challenges
Despite  these  promising  and  exciting  results,  few 
pharma  co  genomic biomarkers are so far in clinical use, 
as highlighted by Urs Meyer. This was a common theme 
mentioned by various researchers at the meeting: many 
patients that could benefit from personalized medicine 
do not in practice. It is as if pharmacogenomics informa­
tion  has  been  lost  in  the  translation  from  scientific 
research to the clinical setting.
The  meeting  gave  an  opportunity  to  identify  further 
obstacles  on  the  path  to  the  promised  land  of 
Figure 1. Number of GWASs from the NHGRI catalog 
[http://genome.gov/gwastudies] catalog. The number of 
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North  Carolina,  Chapel  Hill,  USA)  and  Urs  Meyer 
provided  insights  into  the  next  challenges.  The  first  is 
probably  biostatistical.  Tremendous  efforts  have  been 
made  to  identify  the  association  between  genomic 
markers  and  drug­related  phenotypes.  However, 
association  is  not  prediction.  To  provide  meaningful 
insights, a test for disease risk needs to accurately identify 
positive cases and, at the same time, provide a low false 
positive rate. So far, very few of the identified pharmaco­
genomics markers meet these requirements and we are, 
therefore, still far from personalized medicine. Current 
markers can accurately identify sub­groups of high­risk 
patients  but  the  predictive  power  to  individualize  risk 
remains weak. It is likely that the availability of thousands 
of  human  sequences  combined  with  information  on 
epigenetic variability (as presented by Magnus Ingelman­
Sundberg, Karolinska Institute, Stockholm, Sweden) will 
explain some of the missing heritability and provide new 
genomic  markers  for  pharmacogenomics.  International 
collaborations and networks (such as the Global Alliance 
in Pharmacogenomics or the Pharmacogenetics Research 
Network­RIKEN collaboration) will contribute to larger 
scale studies. In the era of evidence­based medicine, the 
road  to  personalized  medicine  now  depends  on  the 
development  of  biomarker  assays  that  can  identify 
patients at risk with high sensitivity and specificity. As 
drugs must prove themselves in clinical trials before they 
can  be  sold,  the  clinical  relevance  of  genetic  testing 
should  be  tested  prospectively  in  adequately  powered 
randomized studies. Because of the multifactorial nature 
of  drug­related  phenotypes,  the  development  of  global 
risk assessment scores based on traditional clinical risk 
factors,  environmental  and  lifestyle  factors,  biological 
and  genetics  information  should  also  be  considered  in 
order to increase predictive accuracy.
The  second  challenge  is  financial.  On  one  hand,  the 
direct costs for genetic testing have been decreasing in 
the past few years. The cost of genetic testing depends on 
the  nature  and  complexity  of  the  test  but  compares 
favorably  to  other  biological  or  medical  investigations. 
Some  companies  now  offer  DNA  scans  for  less  than 
$1,000. On the other hand, as stated by various partici­
pants,  very  few  studies  have  addressed  the  cost­
effectiveness of pharmacogenomics testing [13]. Evidence 
of cost­effectiveness, if provided, will obviously compel 
public authorities to promote personalized medicine, but 
it will also lead them to consider how to cover its costs. 
Finally, turning science into personalized healthcare will 
require  important  resources.  Personalized  medicine  is 
entering  what  is  classically  called  the  ‘valley  of  death’, 
referring  to  the  funding  gap  between  a  promised 
discovery  and  its  commercial  potential.  Personalized 
medicine  needs  specific  partners  to  get  through  this 
stage.  Pharmaceutical  companies,  non­profit  organiza­
tions, policy makers and healthcare communities should 
all collaborate to ensure pharmacogenomics information 
is translated into public health benefits.
We can also list several other challenges: the research 
funding dedicated to personalized medicine evaluation, 
the regulatory oversight, the reimbursement mechanisms 
in  some  healthcare  systems,  the  need  to  improve  the 
health­information  infrastructure  and  the  need  to 
provide  education  and  training  for  practitioners.  All 
these are challenges and decisions that do not depend 
only on pharmacogenomics researchers.
For all these reasons, despite growing evidence for an 
influence  of  pharmacogenomics  on  medicine,  the 
Table 1. Pharmacogenomics information on the top ten selling drugs in the world
Generic  Therapeutic    Genetic  Drug-induced  Type of  Genetic 
name  class  Indications  influence?  phenotype  studies  variant
Atorvastatin  Statins  Dyslipidemia  Yes  Myopathy  GWAS and candidate gene   SLCO1B1 (drug 
            transporter)
Clopidogrel  Anti-platelet agent  Atherothombosis  Yes  Resistance to   GWAS and candidate gene  CYP2C19 (hepatic
        treatment    enzyme)
Esomeprazole  Proton pump inhibitor  Gastric ulcer  Yes  Drug efficacy  Candidate gene  CYP2C19 (hepatic 
            enzyme)
Fluticasone/Salmeterol Bronchodilator  Asthma  Possible  Drug efficacy  Candidate gene  Beta-2  
            adrenoreceptor
Etanercept  TNF antagonist  Rheumatoid arthritis  Possible  Drug efficacy  GWAS and candidate gene  MAFB
Olanzapine  Psychotropes  Mental disorders  Yes  Drug efficacy  GWAS and candidate gene  ANKS1B; CNTNAP5
Risperidone  Psychotropes  Mental disorders  Yes  Drug efficacy  GWAS and candidate gene  ANKS1B; CNTNAP5
Darbopoetin  Erythropoetin  Anemia  ?  -  -  -
Venlafaxin  Anti-depressant  Depression  Possible  Drug efficacy  Candidate gene  CYP2D6; dopamine/
            serotonin transporter
Amlodipine  Anti-hypertensive  Hypertensive  ?  Drug efficacy  Candidate gene  NOS1AP
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process. However, the new discoveries discussed at this 
meeting  provide  meaningful  insights  that  will  increase 
doctors’  ability  to  personalize  treatment  in  a  not­too­
distant future.
Abbreviations
GWAS, genome-wide association study.
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